209 related articles for article (PubMed ID: 33187540)
1. CRIPTO antagonist ALK4
Balcioglu O; Heinz RE; Freeman DW; Gates BL; Hagos BM; Booker E; Mirzaei Mehrabad E; Diesen HT; Bhakta K; Ranganathan S; Kachi M; Leblanc M; Gray PC; Spike BT
Breast Cancer Res; 2020 Nov; 22(1):125. PubMed ID: 33187540
[TBL] [Abstract][Full Text] [Related]
2. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
[TBL] [Abstract][Full Text] [Related]
3. Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo.
Adkins HB; Bianco C; Schiffer SG; Rayhorn P; Zafari M; Cheung AE; Orozco O; Olson D; De Luca A; Chen LL; Miatkowski K; Benjamin C; Normanno N; Williams KP; Jarpe M; LePage D; Salomon D; Sanicola M
J Clin Invest; 2003 Aug; 112(4):575-87. PubMed ID: 12925698
[TBL] [Abstract][Full Text] [Related]
4. Sulforaphane Suppresses the Growth of Triple-negative Breast Cancer Stem-like Cells
Castro NP; Rangel MC; Merchant AS; MacKinnon G; Cuttitta F; Salomon DS; Kim YS
Cancer Prev Res (Phila); 2019 Mar; 12(3):147-158. PubMed ID: 30679159
[TBL] [Abstract][Full Text] [Related]
5. Cripto forms a complex with activin and type II activin receptors and can block activin signaling.
Gray PC; Harrison CA; Vale W
Proc Natl Acad Sci U S A; 2003 Apr; 100(9):5193-8. PubMed ID: 12682303
[TBL] [Abstract][Full Text] [Related]
6. Structure-based design of small bicyclic peptide inhibitors of Cripto-1 activity.
Iaccarino E; Calvanese L; Untiveros G; Falcigno L; D'Auria G; Latino D; Sivaccumar JP; Strizzi L; Ruvo M; Sandomenico A
Biochem J; 2020 Apr; 477(8):1391-1407. PubMed ID: 32215602
[TBL] [Abstract][Full Text] [Related]
7. Cripto is a noncompetitive activin antagonist that forms analogous signaling complexes with activin and nodal.
Kelber JA; Shani G; Booker EC; Vale WW; Gray PC
J Biol Chem; 2008 Feb; 283(8):4490-500. PubMed ID: 18089557
[TBL] [Abstract][Full Text] [Related]
8. Cripto-1 activates nodal- and ALK4-dependent and -independent signaling pathways in mammary epithelial Cells.
Bianco C; Adkins HB; Wechselberger C; Seno M; Normanno N; De Luca A; Sun Y; Khan N; Kenney N; Ebert A; Williams KP; Sanicola M; Salomon DS
Mol Cell Biol; 2002 Apr; 22(8):2586-97. PubMed ID: 11909953
[TBL] [Abstract][Full Text] [Related]
9. Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer.
Xiang L; Gilkes DM; Chaturvedi P; Luo W; Hu H; Takano N; Liang H; Semenza GL
J Mol Med (Berl); 2014 Feb; 92(2):151-64. PubMed ID: 24248265
[TBL] [Abstract][Full Text] [Related]
10. CRIPTO/GRP78 signaling maintains fetal and adult mammary stem cells ex vivo.
Spike BT; Kelber JA; Booker E; Kalathur M; Rodewald R; Lipianskaya J; La J; He M; Wright T; Klemke R; Wahl GM; Gray PC
Stem Cell Reports; 2014 Apr; 2(4):427-39. PubMed ID: 24749068
[TBL] [Abstract][Full Text] [Related]
11. ActRIIB:ALK4-Fc alleviates muscle dysfunction and comorbidities in murine models of neuromuscular disorders.
Li J; Fredericks M; Cannell M; Wang K; Sako D; Maguire MC; Grenha R; Liharska K; Krishnan L; Bloom T; Belcheva EP; Martinez PA; Castonguay R; Keates S; Alexander MJ; Choi H; Grinberg AV; Pearsall RS; Oh P; Kumar R; Suragani RN
J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33586684
[TBL] [Abstract][Full Text] [Related]
12. FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4.
McClements L; Annett S; Yakkundi A; O'Rourke M; Valentine A; Moustafa N; Alqudah A; Simões BM; Furlong F; Short A; McIntosh SA; McCarthy HO; Clarke RB; Robson T
BMC Cancer; 2019 Apr; 19(1):351. PubMed ID: 30975104
[TBL] [Abstract][Full Text] [Related]
13. Exogenous Cripto-1 Suppresses Self-Renewal of Cancer Stem Cell Model.
Alam MJ; Takahashi R; Afify SM; Oo AKK; Kumon K; Nawara HM; Khayrani AC; Du J; Zahra MH; Seno A; Salomon DS; Seno M
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30373174
[TBL] [Abstract][Full Text] [Related]
14. Cripto-1 contributes to stemness in hepatocellular carcinoma by stabilizing Dishevelled-3 and activating Wnt/β-catenin pathway.
Lo RC; Leung CO; Chan KK; Ho DW; Wong CM; Lee TK; Ng IO
Cell Death Differ; 2018 Aug; 25(8):1426-1441. PubMed ID: 29445127
[TBL] [Abstract][Full Text] [Related]
15. Development of conformational antibodies targeting Cripto-1 with neutralizing effects in vitro.
Focà G; Iaccarino E; Focà A; Sanguigno L; Untiveros G; Cuevas-Nunez M; Strizzi L; Leonardi A; Ruvo M; Sandomenico A
Biochimie; 2019 Mar; 158():246-256. PubMed ID: 30703478
[TBL] [Abstract][Full Text] [Related]
16. Cripto-1 acts as a functional marker of cancer stem-like cells and predicts prognosis of the patients in esophageal squamous cell carcinoma.
Liu Q; Cui X; Yu X; Bian BS; Qian F; Hu XG; Ji CD; Yang L; Ren Y; Cui W; Zhang X; Zhang P; Wang JM; Cui YH; Bian XW
Mol Cancer; 2017 Apr; 16(1):81. PubMed ID: 28431580
[TBL] [Abstract][Full Text] [Related]
17. Cripto-1 Plasmid DNA Vaccination Targets Metastasis and Cancer Stem Cells in Murine Mammary Carcinoma.
Witt K; Ligtenberg MA; Conti L; Lanzardo S; Ruiu R; Wallmann T; Tufvesson-Stiller H; Chambers BJ; Rolny C; Lladser A; Lundqvist A; Cavallo F; Kiessling R
Cancer Immunol Res; 2018 Nov; 6(11):1417-1425. PubMed ID: 30143536
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a natural small-molecule compound that suppresses tumor EMT, stemness and metastasis by inhibiting TGFβ/BMP signaling in triple-negative breast cancer.
Di L; Liu LJ; Yan YM; Fu R; Li Y; Xu Y; Cheng YX; Wu ZQ
J Exp Clin Cancer Res; 2019 Mar; 38(1):134. PubMed ID: 30898152
[TBL] [Abstract][Full Text] [Related]
19. The multifaceted role of the embryonic gene Cripto-1 in cancer, stem cells and epithelial-mesenchymal transition.
Klauzinska M; Castro NP; Rangel MC; Spike BT; Gray PC; Bertolette D; Cuttitta F; Salomon D
Semin Cancer Biol; 2014 Dec; 29():51-8. PubMed ID: 25153355
[TBL] [Abstract][Full Text] [Related]
20. An agent-based model of triple-negative breast cancer: the interplay between chemokine receptor CCR5 expression, cancer stem cells, and hypoxia.
Norton KA; Wallace T; Pandey NB; Popel AS
BMC Syst Biol; 2017 Jul; 11(1):68. PubMed ID: 28693495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
